Blinatumomab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Blinatumomab |
| DrugBank ID | DB09052 |
| Brand Names (EU) | Blincyto |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 95.20% |
Approved Indication (EMA)
Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options. Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 95.20% | DL |
| 2 | Glanzmann thrombasthenia | 95.02% | DL |
| 3 | pseudo-von Willebrand disease | 94.13% | DL |
| 4 | drug-induced osteoporosis | 92.70% | DL |
| 5 | severe nonproliferative diabetic retinopathy | 89.25% | DL |
| 6 | psoriasis | 88.92% | DL |
| 7 | Ledderhose disease | 88.41% | DL |
| 8 | hemorrhagic disorder due to a constitutional thrombocytopenia | 87.88% | DL |
| 9 | penile fibromatosis | 87.80% | DL |
| 10 | bleeding diathesis due to a collagen receptor defect | 87.72% | DL |
| 11 | infantile digital fibromatosis | 87.27% | DL |
| 12 | bronchitis | 87.23% | DL |
| 13 | fetal and neonatal alloimmune thrombocytopenia | 87.21% | DL |
| 14 | palmar fibromatosis | 87.03% | DL |
| 15 | indolent plasma cell myeloma | 86.58% | DL |
| 16 | plasma cell myeloma | 86.48% | DL |
| 17 | HER2 positive breast carcinoma | 86.19% | DL |
| 18 | Scott syndrome | 85.64% | DL |
| 19 | pityriasis lichenoides | 85.56% | DL |
| 20 | inherited thrombophilia | 85.17% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.